Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripertamab in Neuromyelitis Optica Spectrum Disorders
NCT07685678Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Jan 2030
01
Overview
A Phase 2 trial of ripertamab in Neuromyelitis Optica Spectrum Disorder (NMOSD). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ripertamab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07685678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685678.